Key statistics
As of last trade, Neurocrine Biosciences Inc (N1BI34:SAO) traded at 33.66, 31.28% above the 52 week low of 25.64 set on Apr 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 33.69 |
|---|---|
| High | 33.69 |
| Low | 33.66 |
| Bid | 34.74 |
| Offer | 34.86 |
| Previous close | 33.66 |
| Average volume | 306.33 |
|---|---|
| Shares outstanding | -- |
| Free float | -- |
| P/E (TTM) | -- |
| Market cap | -- |
| EPS (TTM) | -- |
Data delayed at least 15 minutes, as of Mar 03 2026 19:31 GMT.
More ▼
Press releases
- Neurocrine Biosciences to Present at Upcoming Investor Conferences in March
- Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
- Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
- Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results
- Neurocrine Biosciences Presents Head-to-Head INGREZZA® (valbenazine) Capsules Data Demonstrating Higher VMAT2 Target Occupancy Compared to AUSTEDO XR
- Neurocrine Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy
- Neurocrine Biosciences Showcases R&D Transformation Driving Innovation Across Neuroscience and Endocrinology
- Neurocrine Biosciences to Host R&D Day on December 16
More ▼
